Evidence map›Paper›PMID 32184631›Full record

ArticleOncoTargets and therapy2020

TIM-3 Participates in the Invasion and Metastasis of Nasopharyngeal Carcinoma via SMAD7/SMAD2/SNAIL1 Axis-Mediated Epithelial-Mesenchymal Transition.

Yangyang Xiao, Jilin Qing, Baoxuan Li, Liuyan Chen, Shengzhou Nong, Wenhui Yang, Xiaogang Tang, Zhizhong Chen

Open access · goldAbstract read
In one paragraph

Article in OncoTargets and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. The potential role of miR-155 in the tumorigenesis of cervical cancer.Frontiers in cell and developmental biology · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yangyang Xiao *Department of Clinical Laboratory, People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi 530021, People's Republic of China.ORCID 0000-0001-9821-1479
Jilin Qing *Center for Reproductive Medicine and Genetics, People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi 530021, People's Republic of China.
Baoxuan LiDepartment of Ophthalmology, Binzhou Medical University Hospital, Binzhou, Shandong 256603, People's Republic of China.
Liuyan ChenDepartment of Clinical Laboratory, People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi 530021, People's Republic of China.
Shengzhou NongDepartment of Clinical Laboratory, People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi 530021, People's Republic of China.
Wenhui YangDepartment of Clinical Laboratory, People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi 530021, People's Republic of China.
Xiaogang TangDepartment of Intensive Care Unit, People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi 530021, People's Republic of China.
Zhizhong ChenDepartment of Clinical Laboratory, People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi 530021, People's Republic of China.
The People's Hospital of Guangxi Zhuang Autonomous Region · CNBinzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundT-cell immunoglobulin and mucin domain-containing molecule-3 (TIM-3) was originally found to negatively regulate immune response and mediate immune escape in tumors. Subsequently, an increasing body of evidence has shown that TIM-3 exerts positive functions in the development and progression of several tumors. However, the role of TIM-3 in nasopharyngeal carcinoma (NPC) remains unknown.

methodsData from the Cancer Genome Atlas-head and neck squamous cell carcinoma and immunohistochemistry were analyzed to compare the expression of TIM-3 in NPC and non-cancerous nasopharyngitis tissues. Cell proliferation was evaluated using the Cell counting kit-8 in vitro and xenograft experiment in nude mice in vivo. Flow cytometry was used to evaluate the cell cycle. The migration and invasion of NPC cells were assessed through wound healing and Transwell assays. In addition, Western blotting was used to analyze the expression of specific proteins.

resultsHigher expression of TIM-3 was detected in NPC tissues than normal nasopharyngeal tissues and positively correlated with the clinical stage and T classification; however, it was not correlated with gender, age, and N classification. Furthermore, overexpression of TIM-3 using lentiviral vectors increased the malignancy of 6-10B and CNE-2 cell lines that lowly express TIM-3, by promoting cell proliferation, migration, and invasion in vitro and in vivo. In addition, overexpression of TIM-3 was associated with upregulation of matrix metalloproteinase 9 (MMP9) and MMP2, and led to epithelial-mesenchymal transition (EMT) by increasing the levels of mesenchymal markers (ie, N-cadherin, Vimentin) and decreasing those of the epithelial marker E-cadherin. Further study showed that SMAD7 was downregulated in the TIM-3 overexpression group. Relatively, phosphorylated SMAD2 and downstream molecule SNAIL1 were also upregulated in this group.

conclusionTIM-3 exerts a tumor-promoting function in NPC by mediating changes in the SMAD7/SMAD2/SNAIL1 axis. These findings provide a new idea for the study of invasion, metastasis, and treatment of NPC.

Indexed as

epithelial-mesenchymal transitioninvasionmetastasisnasopharyngeal carcinomaT-cell immunoglobulin and mucin-domain containing molecule-3

Identifiers

PMID32184631
PMCPMC7064287
OpenAlexW3009393163

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.